Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1975 1
1976 2
1978 1
1980 1
1981 1
1987 1
1989 2
1990 3
1991 1
1994 4
1995 7
1996 13
1997 1
1998 4
1999 2
2000 1
2001 2
2003 9
2004 1
2005 4
2006 3
2007 8
2008 1
2009 2
2011 6
2012 6
2013 4
2014 5
2015 9
2016 12
2017 6
2018 11
2019 15
2020 7
2021 9
2022 7
2023 8
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

165 results

Results by year

Filters applied: . Clear all
Page 1
Hyperhidrosis.
Pariser DM. Pariser DM. Dermatol Clin. 2014 Oct;32(4):xi. doi: 10.1016/j.det.2014.07.001. Dermatol Clin. 2014. PMID: 25152352 No abstract available.
Effect of Roflumilast Cream vs Vehicle Cream on Chronic Plaque Psoriasis: The DERMIS-1 and DERMIS-2 Randomized Clinical Trials.
Lebwohl MG, Kircik LH, Moore AY, Stein Gold L, Draelos ZD, Gooderham MJ, Papp KA, Bagel J, Bhatia N, Del Rosso JQ, Ferris LK, Green LJ, Hebert AA, Jones T, Kempers SE, Pariser DM, Yamauchi PS, Zirwas M, Albrecht L, Devani AR, Lomaga M, Feng A, Snyder S, Burnett P, Higham RC, Berk DR. Lebwohl MG, et al. Among authors: pariser dm. JAMA. 2022 Sep 20;328(11):1073-1084. doi: 10.1001/jama.2022.15632. JAMA. 2022. PMID: 36125472 Free PMC article.
Efficacy of Roflumilast Foam, 0.3%, in Patients With Seborrheic Dermatitis: A Double-blind, Vehicle-Controlled Phase 2a Randomized Clinical Trial.
Zirwas MJ, Draelos ZD, DuBois J, Kircik LH, Moore AY, Stein Gold L, Alonso-Llamazares J, Bukhalo M, Bruce S, Eads K, Green LJ, Guenthner ST, Ferris LK, Forman SB, Kempers SE, Lain E, Lynde CW, Pariser DM, Toth DP, Yamauchi PS, Higham RC, Krupa D, Burnett P, Berk DR. Zirwas MJ, et al. Among authors: pariser dm. JAMA Dermatol. 2023 Jun 1;159(6):613-620. doi: 10.1001/jamadermatol.2023.0846. JAMA Dermatol. 2023. PMID: 37133856 Free PMC article. Clinical Trial.
Safety and efficacy of bimekizumab through 2 years in patients with moderate-to-severe plaque psoriasis: longer-term results from the BE SURE randomized controlled trial and the open-label extension from the BE BRIGHT trial.
Thaçi D, Vender R, de Rie MA, Conrad C, Pariser DM, Strober B, Vanvoorden V, Wang M, Madden C, de Cuyper D, Kimball AB. Thaçi D, et al. Among authors: pariser dm. Br J Dermatol. 2023 Jan 23;188(1):22-31. doi: 10.1093/bjd/ljac021. Br J Dermatol. 2023. PMID: 36689515 Clinical Trial.
Efficacy and Safety of a Fixed-Dose Clindamycin Phosphate 1.2%, Benzoyl Peroxide 3.1%, and Adapalene 0.15% Gel for Moderate-to-Severe Acne: A Randomized Phase II Study of the First Triple-Combination Drug.
Stein Gold L, Baldwin H, Kircik LH, Weiss JS, Pariser DM, Callender V, Lain E, Gold M, Beer K, Draelos Z, Sadick N, Pillai R, Bhatt V, Tanghetti EA. Stein Gold L, et al. Among authors: pariser dm. Am J Clin Dermatol. 2022 Jan;23(1):93-104. doi: 10.1007/s40257-021-00650-3. Epub 2021 Oct 21. Am J Clin Dermatol. 2022. PMID: 34674160 Free PMC article. Clinical Trial.
The effects of finasteride on scalp skin and serum androgen levels in men with androgenetic alopecia.
Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, Thiboutot DM, Lowe N, Jacobson C, Whiting D, Stieglitz S, Kraus SJ, Griffin EI, Weiss D, Carrington P, Gencheff C, Cole GW, Pariser DM, Epstein ES, Tanaka W, Dallob A, Vandormael K, Geissler L, Waldstreicher J. Drake L, et al. Among authors: pariser dm. J Am Acad Dermatol. 1999 Oct;41(4):550-4. J Am Acad Dermatol. 1999. PMID: 10495374 Clinical Trial.
Building a Group Practice and Going Big.
Pariser DM. Pariser DM. Dermatol Clin. 2023 Oct;41(4):635-641. doi: 10.1016/j.det.2023.05.002. Epub 2023 Jul 3. Dermatol Clin. 2023. PMID: 37718021 Review.
Onchomycosis: an overview.
Elewski BE, Rich P, Tosti A, Pariser DM, Scher R, Daniel RC, Gupta AK. Elewski BE, et al. Among authors: pariser dm. J Drugs Dermatol. 2013 Jul 1;12(7):s96-103. J Drugs Dermatol. 2013. PMID: 23884508
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb study.
Kircik LH, Alonso-Llamazares J, Bhatia N, Bukhalo M, Devani AR, Draelos ZD, DuBois J, Gooderham MJ, Kempers SE, Lain E, Lee M, Moore A, Murrell DF, Papp KA, Pariser DM, Sinclair R, Zirwas M, Burnett P, Higham RC, Krupa D, Berk DR. Kircik LH, et al. Among authors: pariser dm. Br J Dermatol. 2023 Sep 15;189(4):392-399. doi: 10.1093/bjd/ljad182. Br J Dermatol. 2023. PMID: 37279795 Clinical Trial.
Integrating Skin Cancer-Related Technologies into Clinical Practice.
Winkelmann RR, Farberg AS, Glazer AM, Cockerell CJ, Sober AJ, Siegel DM, Leachman SA, High WA, Markowitz O, Berman B, Pariser DM, Goldenberg G, Rosen T, Rigel DS. Winkelmann RR, et al. Among authors: pariser dm. Dermatol Clin. 2017 Oct;35(4):565-576. doi: 10.1016/j.det.2017.06.018. Epub 2017 Aug 12. Dermatol Clin. 2017. PMID: 28886814 Review.
165 results